These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
198 related articles for article (PubMed ID: 24464804)
1. High daily dose and being a substrate of cytochrome P450 enzymes are two important predictors of drug-induced liver injury. Yu K; Geng X; Chen M; Zhang J; Wang B; Ilic K; Tong W Drug Metab Dispos; 2014 Apr; 42(4):744-50. PubMed ID: 24464804 [TBL] [Abstract][Full Text] [Related]
2. Relationship between daily dose of oral medications and idiosyncratic drug-induced liver injury: search for signals. Lammert C; Einarsson S; Saha C; Niklasson A; Bjornsson E; Chalasani N Hepatology; 2008 Jun; 47(6):2003-9. PubMed ID: 18454504 [TBL] [Abstract][Full Text] [Related]
3. Drug-induced liver injury: the role of drug metabolism and transport. Corsini A; Bortolini M J Clin Pharmacol; 2013 May; 53(5):463-74. PubMed ID: 23436293 [TBL] [Abstract][Full Text] [Related]
4. Associations of Drug Lipophilicity and Extent of Metabolism with Drug-Induced Liver Injury. McEuen K; Borlak J; Tong W; Chen M Int J Mol Sci; 2017 Jun; 18(7):. PubMed ID: 28640208 [TBL] [Abstract][Full Text] [Related]
5. Association of CYP1A1 and CYP1B1 inhibition in in vitro assays with drug-induced liver injury. Shimizu Y; Sasaki T; Yonekawa E; Yamazaki H; Ogura R; Watanabe M; Hosaka T; Shizu R; Takeshita JI; Yoshinari K J Toxicol Sci; 2021; 46(4):167-176. PubMed ID: 33814510 [TBL] [Abstract][Full Text] [Related]
6. Development of Decision Forest Models for Prediction of Drug-Induced Liver Injury in Humans Using A Large Set of FDA-approved Drugs. Hong H; Thakkar S; Chen M; Tong W Sci Rep; 2017 Dec; 7(1):17311. PubMed ID: 29229971 [TBL] [Abstract][Full Text] [Related]
7. High lipophilicity and high daily dose of oral medications are associated with significant risk for drug-induced liver injury. Chen M; Borlak J; Tong W Hepatology; 2013 Jul; 58(1):388-96. PubMed ID: 23258593 [TBL] [Abstract][Full Text] [Related]
8. Utility of human cytochrome P450 inhibition data in the assessment of drug-induced liver injury. Kaito S; Takeshita JI; Iwata M; Sasaki T; Hosaka T; Shizu R; Yoshinari K Xenobiotica; 2024 Jul; 54(7):411-419. PubMed ID: 38315106 [TBL] [Abstract][Full Text] [Related]
9. The Liver Toxicity Knowledge Base (LKTB) and drug-induced liver injury (DILI) classification for assessment of human liver injury. Thakkar S; Chen M; Fang H; Liu Z; Roberts R; Tong W Expert Rev Gastroenterol Hepatol; 2018 Jan; 12(1):31-38. PubMed ID: 28931315 [TBL] [Abstract][Full Text] [Related]
10. Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds. Sakatis MZ; Reese MJ; Harrell AW; Taylor MA; Baines IA; Chen L; Bloomer JC; Yang EY; Ellens HM; Ambroso JL; Lovatt CA; Ayrton AD; Clarke SE Chem Res Toxicol; 2012 Oct; 25(10):2067-82. PubMed ID: 22931300 [TBL] [Abstract][Full Text] [Related]
11. Measures of BSEP Inhibition In Vitro Are Not Useful Predictors of DILI. Chan R; Benet LZ Toxicol Sci; 2018 Apr; 162(2):499-508. PubMed ID: 29272540 [TBL] [Abstract][Full Text] [Related]
12. Development of a cell-based assay system considering drug metabolism and immune- and inflammatory-related factors for the risk assessment of drug-induced liver injury. Yano A; Oda S; Fukami T; Nakajima M; Yokoi T Toxicol Lett; 2014 Jul; 228(1):13-24. PubMed ID: 24747151 [TBL] [Abstract][Full Text] [Related]
13. Prevalence of Non-Cytochrome P450-Mediated Metabolism in Food and Drug Administration-Approved Oral and Intravenous Drugs: 2006-2015. Cerny MA Drug Metab Dispos; 2016 Aug; 44(8):1246-52. PubMed ID: 27084892 [TBL] [Abstract][Full Text] [Related]
14. Setting Clinical Exposure Levels of Concern for Drug-Induced Liver Injury (DILI) Using Mechanistic in vitro Assays. Shah F; Leung L; Barton HA; Will Y; Rodrigues AD; Greene N; Aleo MD Toxicol Sci; 2015 Oct; 147(2):500-14. PubMed ID: 26206150 [TBL] [Abstract][Full Text] [Related]
15. Role of cytochrome P450-mediated metabolism and involvement of reactive metabolite formations on antiepileptic drug-induced liver injuries. Sasaki E; Yokoi T J Toxicol Sci; 2018; 43(2):75-87. PubMed ID: 29479037 [TBL] [Abstract][Full Text] [Related]
16. Oral medications with significant hepatic metabolism at higher risk for hepatic adverse events. Lammert C; Bjornsson E; Niklasson A; Chalasani N Hepatology; 2010 Feb; 51(2):615-20. PubMed ID: 19839004 [TBL] [Abstract][Full Text] [Related]
18. Drug interaction with UDP-Glucuronosyltransferase (UGT) enzymes is a predictor of drug-induced liver injury. Olubamiwa AO; Liao TJ; Zhao J; Dehanne P; Noban C; Angin Y; Barberan O; Chen M Hepatology; 2024 Jul; ():. PubMed ID: 39024247 [TBL] [Abstract][Full Text] [Related]
19. [Establishment of animal models of drug-induced liver injury and analysis of possible mechanisms]. Oda S; Yokoi T Yakugaku Zasshi; 2015; 135(4):579-88. PubMed ID: 25832838 [TBL] [Abstract][Full Text] [Related]
20. Predicting and preventing acute drug-induced liver injury: what's new in 2010? Liss G; Rattan S; Lewis JH Expert Opin Drug Metab Toxicol; 2010 Sep; 6(9):1047-61. PubMed ID: 20615079 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]